[
  {
    "ts": null,
    "headline": "Amgen Agrees to Buy Dark Blue Therapeutics in Up to $840 Million Deal",
    "summary": "The acquisition adds a preclinical protein degrader program targeting acute myeloid leukemia to Amgen's oncology pipeline.",
    "url": "https://finnhub.io/api/news?id=a2fcba301e91e28de472bf07a185a51e6710346208b4217a9f14825b6af7c675",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767719246,
      "headline": "Amgen Agrees to Buy Dark Blue Therapeutics in Up to $840 Million Deal",
      "id": 138002020,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The acquisition adds a preclinical protein degrader program targeting acute myeloid leukemia to Amgen's oncology pipeline.",
      "url": "https://finnhub.io/api/news?id=a2fcba301e91e28de472bf07a185a51e6710346208b4217a9f14825b6af7c675"
    }
  },
  {
    "ts": null,
    "headline": "Dark Blue Therapeutics acquired by Amgen for up to $840 million",
    "summary": "Dark Blue Therapeutics (\"Dark Blue\"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen (NASDAQ: AMGN).",
    "url": "https://finnhub.io/api/news?id=836b983de031ee6a50da8c5dc807298f0d81e36da2fd0f35500f8e6d7da7de5c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767709800,
      "headline": "Dark Blue Therapeutics acquired by Amgen for up to $840 million",
      "id": 138000618,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Dark Blue Therapeutics (\"Dark Blue\"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen (NASDAQ: AMGN).",
      "url": "https://finnhub.io/api/news?id=836b983de031ee6a50da8c5dc807298f0d81e36da2fd0f35500f8e6d7da7de5c"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE",
    "summary": "Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.",
    "url": "https://finnhub.io/api/news?id=2c221ab9ac1f1fc821bc22e753ba79fea79ebe5a2c1c8b00722f0bb3aeb778dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767708000,
      "headline": "AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE",
      "id": 138000178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.",
      "url": "https://finnhub.io/api/news?id=2c221ab9ac1f1fc821bc22e753ba79fea79ebe5a2c1c8b00722f0bb3aeb778dc"
    }
  },
  {
    "ts": null,
    "headline": "What to Expect From Amgen's Q4 2025 Earnings Report",
    "summary": "Amgen will release its fourth-quarter earnings soon, and analysts anticipate a low double-digit profit dip.",
    "url": "https://finnhub.io/api/news?id=6e63f6875708d214d4a1e0cd70d00e506812e79007db9685481cee25334d89ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767700877,
      "headline": "What to Expect From Amgen's Q4 2025 Earnings Report",
      "id": 138000619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen will release its fourth-quarter earnings soon, and analysts anticipate a low double-digit profit dip.",
      "url": "https://finnhub.io/api/news?id=6e63f6875708d214d4a1e0cd70d00e506812e79007db9685481cee25334d89ce"
    }
  },
  {
    "ts": null,
    "headline": "Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win",
    "summary": "While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.",
    "url": "https://finnhub.io/api/news?id=1d5d38b1b3a57c84f089697eb63bb6948a8924a27a6c1bfefa2bddd43de136be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767698727,
      "headline": "Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win",
      "id": 137999405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.",
      "url": "https://finnhub.io/api/news?id=1d5d38b1b3a57c84f089697eb63bb6948a8924a27a6c1bfefa2bddd43de136be"
    }
  },
  {
    "ts": null,
    "headline": "Amgen buys protein-degrading startup Dark Blue for up to $840M",
    "summary": "The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that could set it apart from current medications.",
    "url": "https://finnhub.io/api/news?id=d9384e0727008681ba0a802af7f95dec755324eb264ed6127908c8d097306c86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767698220,
      "headline": "Amgen buys protein-degrading startup Dark Blue for up to $840M",
      "id": 138002021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that could set it apart from current medications.",
      "url": "https://finnhub.io/api/news?id=d9384e0727008681ba0a802af7f95dec755324eb264ed6127908c8d097306c86"
    }
  },
  {
    "ts": null,
    "headline": "Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor",
    "summary": "Zenas BioPharma stays a Strong Buy after INDIGO phase 3 success for Obexelimab in IgG4-RD. Click here to read an analysis of ZBIO stock now.",
    "url": "https://finnhub.io/api/news?id=df4d70cce29526e598d7b6c705a3697353596c004529e45dd42468cb0997baa5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767675519,
      "headline": "Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor",
      "id": 137998683,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241469509/image_2241469509.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Zenas BioPharma stays a Strong Buy after INDIGO phase 3 success for Obexelimab in IgG4-RD. Click here to read an analysis of ZBIO stock now.",
      "url": "https://finnhub.io/api/news?id=df4d70cce29526e598d7b6c705a3697353596c004529e45dd42468cb0997baa5"
    }
  }
]